Lakefront Biotherapeutics (LKFT) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Lakefront Biotherapeutics (LKFT) over the past year, gaining 28.0% versus a loss of 12.6%. Over five years, XERS leads with a +424.0% price change compared with -44.5% for LKFT. Lakefront Biotherapeutics is the larger company by market cap ($1.95 billion vs $1.91 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | XERS |
|---|---|---|
| Share price | $29.73 | $10.48 |
| Market cap | $1.95B | $1.91B |
| 1-day change | +0.75% | +2.85% |
| YTD return | -9.08% | +33.50% |
| 1-year return | -12.61% | +27.96% |
| 5-year return | -44.45% | +424.00% |
| P/E ratio (TTM) | 2.83 | — |
| Forward P/E | — | 28.32 |
| EPS (TTM) | $10.52 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | — | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $36.24 | $11.33 |
| 52-week low | $25.68 | $5.25 |
| Distance from 52-week high | -17.96% | -7.50% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +1.51% | +22.71% |
| Average volume | 275.47K | 2.18M |
| Shares outstanding | 65.48M | 182.32M |
| Employees | 196 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed LKFT by 40.6 percentage points over the past year.
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
LKFT vs XERS FAQ
Which is bigger, Lakefront Biotherapeutics or Xeris Biopharma?
Lakefront Biotherapeutics (LKFT) is larger, with a market capitalization of $1.95B compared with $1.91B for Xeris Biopharma (XERS).
Which stock has performed better over the past year, LKFT or XERS?
XERS returned +27.96% over the past 12 months, compared with -12.61% for LKFT (price return, excluding dividends). Past performance does not predict future results.
Are Lakefront Biotherapeutics and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.